ACCUGENOMICS Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ACCUGENOMICS's estimated annual revenue is currently $1.4M per year.(i)
  • ACCUGENOMICS's estimated revenue per employee is $155,000

Employee Data

  • ACCUGENOMICS has 9 Employees.(i)
  • ACCUGENOMICS grew their employee count by 0% last year.

ACCUGENOMICS's People

NameTitleEmail/Phone
1
SVP Business Development & CommercialReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is ACCUGENOMICS?

AccuGenomics is a developer of a unique spike-in control technology that dramatically improves the accuracy and performance of clinical sequencing tests for low abundance biomarkers such as circulating tumor DNA (ctDNA) and low titer infectious pathogens such as SARS-CoV-2. Standardized Nucleic Acid Quantification for Sequencing (SNAQâ„¢-SEQ) is an innovative QC method that uses mixtures of synthetic DNA or RNA internal standards (MISâ„¢) spiked into each sample prior to NGS library prep. Being mixed with the sample and biochemically identical to the regions of interest, these standards undergo the same processing, handling and reaction conditions as the sample does, to provide the ideal run control approach for NGS-based assays. SNAQ-SEQ spike-in controls provide much higher confidence in the results of sequencing tests, eliminate false positives and dramatically reduce false negatives resulting in better overall accuracy as compared to using external (or no) controls alone.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$1.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M90%N/A
#2
$0.7M950%N/A
#3
$0.7M913%N/A
#4
$1M9N/AN/A
#5
$0.7M913%N/A